MARKET

ALNA

ALNA

Allena
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.400
-0.050
-3.45%
After Hours: 1.410 +0.01 +0.71% 17:36 07/10 EDT
OPEN
1.440
PREV CLOSE
1.450
HIGH
1.450
LOW
1.380
VOLUME
410.55K
TURNOVER
--
52 WEEK HIGH
6.30
52 WEEK LOW
0.5250
MARKET CAP
44.88M
P/E (TTM)
-0.7387
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALNA stock price target is 9.00 with a high estimate of 26.00 and a low estimate of 1.000.

EPS

ALNA News

More
Hedge Funds Nibbling On Allena Pharmaceuticals, Inc. (ALNA)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain
Insider Monkey · 06/15 23:12
Allena Pharmaceuticals Shares Resumed Trading At 1:20 p.m., Shares Down 17% After Company Announces $15M Direct Offering
Benzinga · 06/03 17:34
Allena Pharmaceutical Shares Halted On Volatility After Company Announces $15M Direct Offering
Benzinga · 06/03 17:18
Allena Pharmaceuticals Announces $15.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules; Priced At $2.05/Share
NEWTON, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc.(NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to
Benzinga · 06/03 17:17
Allena Pharmaceuticals Announces $15.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has
GlobeNewswire · 06/03 17:15
50 Stocks Moving In Tuesday's Mid-Day Session
Gainers Tenax Therapeutics Inc (NASDAQ: TENX) shares climbed 42.3% to $2.07 after the company reported results from its Phase 2 trial of Levosimendan. The trial demonstrated a significant reduction in right atrial and pulmonary capillary wedge pressures.
Benzinga · 06/02 16:21
CLDR, AGEN among premarket gainers
Seeking Alpha - Article · 06/02 13:21
The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs
Benzinga · 06/02 12:45

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About ALNA

Allena Pharmaceuticals, Inc. is a late-stage, clinical biopharmaceutical company. The Company is focused on developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. It is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). Its pipeline includes reloxaliase and ALLN-346. Reloxaliase is an oral enzyme therapeutic that is being developed for the treatment of hyperoxaluria. ALLN-346 is designed to be an orally-administered non-absorbed urate-degrading enzyme. ALLN-346 is being developed to degrade urate in the gastrointestinal (GI) tract.
More

Webull offers kinds of Allena Pharmaceuticals Inc stock information, including NASDAQ:ALNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALNA stock methods without spending real money on the virtual paper trading platform.